2018
The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacology & Therapeutics 2018, 190: 148-158. PMID: 29803629, PMCID: PMC6165688, DOI: 10.1016/j.pharmthera.2018.05.010.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntidepressive AgentsBiomarkersDepressionDisease Models, AnimalDrug DevelopmentGlutamic AcidHumansKetamineSynaptic TransmissionConceptsRapid-acting antidepressantsNeurobiology of depressionMechanism of actionChronic stress pathologyRole of glutamateAntidepressant effectsEfficacy findingsGlutamate activationBiomarker findingsNeurobiology of stressVivo pharmacodynamicsCurrent perspective paperKetamineChronic stressReproducible biomarkersBehavioral effectsGlutamate inhibitionDepressionStress pathologyAntidepressantsNeurobiologyInhibitionActivationPharmacodynamicsPharmacokinetics
2017
Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic
Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Current Psychiatry Reports 2017, 19: 74. PMID: 28844076, PMCID: PMC5904792, DOI: 10.1007/s11920-017-0829-z.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDisease Models, AnimalExcitatory Amino Acid AntagonistsHumansKetamineNeurobiologyStress Disorders, Post-TraumaticSynaptic TransmissionConceptsSynaptic connectivityRapid-acting treatmentPathophysiology of PTSDPotential clinical importanceTreatment of PTSDSynaptic lossPurpose of ReviewStudiesDisconnection syndromeClinical importanceNovel pharmacotherapeuticsNovel therapeuticsPTSD symptomsRecent FindingsHerePTSDPathophysiologyKetamineTreatmentDisordersTherapeutic applicationsStress-related lossesSyndromeSymptomsPharmacotherapeutics
2016
Implication of NOTCH1 gene in susceptibility to anxiety and depression among sexual abuse victims
Steine IM, Zayats T, Stansberg C, Pallesen S, Mrdalj J, Håvik B, Soulé J, Haavik J, Milde AM, Skrede S, Murison R, Krystal J, Grønli J. Implication of NOTCH1 gene in susceptibility to anxiety and depression among sexual abuse victims. Translational Psychiatry 2016, 6: e977-e977. PMID: 27959334, PMCID: PMC5290341, DOI: 10.1038/tp.2016.248.Peer-Reviewed Original ResearchMeSH KeywordsAllelesAnimalsAnxiety DisordersBrainDepressive DisorderDisease Models, AnimalFemaleGene ExpressionGenetic Predisposition to DiseaseHumansLife Change EventsMaleNeurodevelopmental DisordersPolymorphism, Single NucleotideRats, WistarReceptor, Notch1Sex OffensesTranslational Research, BiomedicalConceptsSingle nucleotide polymorphismsDifferent early-life conditionsGene expressionEarly-life conditionsBrain gene expressionGenetic association studiesCandidate genesAssociation studiesNeural developmentDifferential expressionTag single nucleotide polymorphismsBrain of rodentsGenesHuman samplesFalse discovery rateNotch1 geneSymptoms of anxietyExpressionSignificance analysisDiscovery ratePotential importanceEarly life stressMeans of correspondencePotential relevancePlk5
2012
Capturing the Angel in “Angel Dust”: Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans
Moghaddam B, Krystal JH. Capturing the Angel in “Angel Dust”: Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans. Schizophrenia Bulletin 2012, 38: 942-949. PMID: 22899397, PMCID: PMC3446228, DOI: 10.1093/schbul/sbs075.Peer-Reviewed Original ResearchMeSH KeywordsAllosteric RegulationAnimalsAntipsychotic AgentsBrief Psychiatric Rating ScaleCerebral CortexDisease Models, AnimalDopamineEmotionsGlutamic AcidHumansKetamineNeurosciencesPhencyclidinePsychoses, Substance-InducedReceptor, Metabotropic Glutamate 5Receptors, Dopamine D2Receptors, Metabotropic GlutamateReceptors, N-Methyl-D-AspartateSchizophreniaSynapsesTranslational Research, BiomedicalConceptsNMDA receptor antagonistReceptor antagonistDopamine hypothesisN-methyl-D-aspartate receptor antagonistGlutamate synaptic functionTranslational neuroscience studiesTreatment of schizophreniaPathophysiology of schizophreniaPotential treatment targetPotential new targetsDopamine antagonistsCortical functionAnimal studiesTreatment targetsClinical testingSynaptic functionAntagonistTranslational toolSchizophreniaTranslational research fundingTranslational researchPotential mechanismsNew targetsAngel dustSystems neuroscience
2011
New Frontiers in Animal Research of Psychiatric Illness
Kaffman A, Krystal J. New Frontiers in Animal Research of Psychiatric Illness. Methods In Molecular Biology 2011, 829: 3-30. PMID: 22231804, PMCID: PMC3337084, DOI: 10.1007/978-1-61779-458-2_1.Peer-Reviewed Original ResearchConceptsPsychiatric illnessAnimal modelsMental illnessHuman psychopathologyValid animal modelCurrent animal modelsNumerous psychiatric disordersMore effective interventionsResearch Domain Criteria projectInternational ClassificationPsychiatric disordersMeasurable endophenotypesIllnessNeurodevelopmental changesSubstance abuseEffective interventionsAnxiety disordersStatistical ManualMolecular changesDevelopmental originsMental disorders diagnostic systemsCircuit developmentTranslational workAnimal researchBehavioral outcomesAdvancing drug discovery for schizophrenia
Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Saw A, Caron MG, George SR, Allen JA, Solis M. Advancing drug discovery for schizophrenia. Annals Of The New York Academy Of Sciences 2011, 1236: 30-43. PMID: 22032400, PMCID: PMC3787879, DOI: 10.1111/j.1749-6632.2011.06216.x.Peer-Reviewed Original ResearchCognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders
Carter CS, Barch DM, Bullmore E, Breiling J, Buchanan RW, Butler P, Cohen JD, Geyer M, Gollub R, Green MF, Jaeger J, Krystal JH, Moore H, Nuechterlein K, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T. Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders. Biological Psychiatry 2011, 70: 7-12. PMID: 21529781, PMCID: PMC3116022, DOI: 10.1016/j.biopsych.2011.01.041.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, PharmacologicalBrain MappingCognition DisordersDisease Models, AnimalDrug DiscoveryHumansSchizophreniaConceptsCognitive Neuroscience Treatment ResearchTreatment researchCognitive neuroscienceTreatment developmentFunctional magnetic resonance imagingSchizophrenia (MATRICS) initiativeSchizophrenia IIPotential confoundsImpaired cognitionCognitionNeural systemsNeural activityPsychometric propertiesMental healthBrain functionTranscranial magnetic simulationNeuroscienceTreatment effectsSchizophreniaMulticenter phase IITranslational researchImproved animal modelsPragmatic issuesBiological psychiatryMagnetic resonance imaging
1997
Noradrenergic Alterations in Posttraumatic Stress Disorder
SOUTHWICK S, MORGAN CA, BREMNER A, GRILLON C, KRYSTAL J, NAGY L, CHARNEY D. Noradrenergic Alterations in Posttraumatic Stress Disorder. Annals Of The New York Academy Of Sciences 1997, 821: 125-141. PMID: 9238199, DOI: 10.1111/j.1749-6632.1997.tb48274.x.Peer-Reviewed Original Research
1990
Serotonin Function and Human Anxiety Disordersa
CHARNEY D, WOODS S, KRYSTAL J, HENINGER G. Serotonin Function and Human Anxiety Disordersa. Annals Of The New York Academy Of Sciences 1990, 600: 558-572. PMID: 2252335, DOI: 10.1111/j.1749-6632.1990.tb16910.x.Peer-Reviewed Original Research